The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 54 | — | 20.1x | Near average | |
Growth | 10 | -52.5% | 5.6% | Below average | |
Quality | 76 | 12.5% | 7.6% | Above average | |
Safety | 32 | 0.2x | 0.4x | Below average | |
Capital Return | 14 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Novavax, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Novavax, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Novavax stock shows stability in the average price target at 18 dollars over the last 30 days, reflecting a wait-and-see approach by the three analysts currently covering the stock. Although the average price target suggests significant upside potential compared to the current price (9.21 dollars), there is wide dispersion in estimates between the low of 11 dollars and the high of 25 dollars, reflecting operational uncertainty.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.